The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder

International Journal of Clinical Practice

Volumn 62, Issue 4, 2008, Pages 623-632

  Sobocki, P ^a,b   Ekman, M ^c,g   Ovanfors, A ^d   Khandker, R ^e   Jonsson B ^f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b European Health Economics   (Sweden)

^c i3 Innovus   (Sweden)

^d Wyeth AB   (Sweden)

^e PFIZER INC   (United States)

^f STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^g NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

VENLAFAXINE;

ADULT; ARTICLE; CLINICAL STUDY; COST UTILITY ANALYSIS; DRUG COST; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; RELAPSE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIMULATION;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; HUMANS; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; RISK FACTORS;

EID: 40449088621     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01711.x     Document Type: Article

References (40)

1. Greenberg PE, Kessler RC, Birnbaum HG et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003 64 : 1465 75.
2. Mueller TI, Leon AC, Keller MB et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999 156 : 1000 6.
3. Paykel ES. Continuation and maintenance therapy in depression. Br Med Bull 2001 57 : 145 59.
4. Frank E, Prien RF, Jarrett RB et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991 48 : 851 5.
5. Vos T, Haby MM, Barendregt JJ et al. The burden of major depression avoidable by longer-term treatment strategies. Arch Gen Psychiatry 2004 61 : 1097 103.
6. Nierenberg AA, Petersen TJ, Alpert JE. Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. J Clin Psychiatry 2003 64 (Suppl. 15 13 7.
7. Solomon DA, Keller MB, Leon AC et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000 157 : 229 33.
8. Kamlet MS, Paul N, Greenhouse J et al. Cost utility analysis of maintenance treatment for recurrent depression. Control Clin Trials 1995 16 : 17 40.
9. Geddes JR, Carney SM, Davies C et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003 361 : 653 61.
10. Sobocki P, Ekman M, Ågren H et al. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract 2006 60 : 791 8.
11. Sobocki P, Ekman M, Ågren H et al. Resource-use and costs associated with patients treated for depression in primary care. Eur J Health Econ 2007 8 : 67 76.
12. Keller M, Yan B, Dunner D et al. Recurrence prevention: Efficacy of Two Years of Maintenance Treatment with Venxalafine XR in Patients with Recurrent Unipolar Major Depression. Toronto, ON : American Psychiatric Association Meeting, 20-25 May 2006.
13. Sobocki P, Ekman M, Ågren H et al. Model to assess the cost-effectiveness of new treatments for depression. Int J Technol Assess Health Care 2006 22 : 469 77.
14. Machado M, Iskedjian M, Ruiz I et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Curr Med Res Opin 2006 22 : 1825 37.
15. Sobocki P, Ekman M, Ågren H et al. Health-related quality-of-life measured with EQ-5D in patients treated for depression in primary care. Value Health 2007 10 : 153 60.
16. Burström K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001 10 : 621 35.
17. SCB. Statistical Year Book of Sweden. Stockholm : SCB, 2006.
18. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997 170 : 205 28.
19. Angst J, Gamma A, Sellaro R et al. Recurrence of bipolar disorders and major depression. A life-long perspective. Eur Arch Psychiatry Clin Neurosci 2003 253 : 236 40.
20. Kessing LV, Andersen PK. The effect of episodes on recurrence in affective disorder: a case register study. J Affect Disord 1999 53 : 225 31.
21. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). Stockholm, 2003.
22. Briggs A, Gray A. Handling uncertainty when performing economic evaluation of health care interventions. Health Technol Assess 1999 3 : 35 60.
23. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997 6 : 327 40.
24. Stewart WF, Ricci JA, Chee E et al. Cost of lost productive work time among US workers with depression. JAMA 2003 289 : 3135 44.
25. Eichler HG, Kong SX, Gerth WC et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004 7 : 518 28.
26. Newhouse JP. US and UK health economics: two disciplines separated by a common language? Health Econ 1998 7 (Suppl. 1 S79 92.
27. Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960-2000. N Engl J Med 2006 355 : 920 7.
28. King JT Jr., Tsevat J, Lave JR et al. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Mak 2005 25 : 667 77.
29. Persson U, Hjelmgren J. Health services need knowledge of how the public values health. Läkartidningen 2003 100 : 3436 7.
30. Han D, Wang EC. Remission from depression: a review of venlafaxine clinical and economic evidence. Pharmacoeconomics 2005 23 : 567 81.
31. Simon GE, Revicki D, Heiligenstein J et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000 22 : 153 62.
32. Reesal RT, Lam RW. Clinical guidelines for the treatment of depressive disorders. II. Principles of management. Can J Psychiatry 2001 46 (Suppl. 1 21S 8S.
33. American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000 157 : 1 45.
34. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol 2000 14 : 3 20.
35. AHCPR. Treatment of Major Depression. AHCPR 93-0551, Vol. 2, No. 5. Rockeville, MD : Agency for Healthcare Policy and Research, 1993.
36. The Swedish Council on Technology Assessment in Health Care (SBU). Behandling av depressionssjukdomar - En systematisk litteraturöversikt (Treatment of depression). SBU report No 166/3. Stockholm : The Swedish Council on Technology Assessment in Health Care (SBU), 2004.
37. Hjalte K, Hjelmgren J, Johansson F et al. Betalningsviljan för ett kvalitetsjusterat levnadsår - en pilotstudie. Institutet för Hälsoekonomi. http://www.ihe.se/publiceringar/ihe_e-rapport_2005_1.htm (accessed April 2005).
38. Dardennes RM, Lafuma A, Fagnani F et al. Economic assessment of a maintenance treatment strategy in prevention of recurrent depressive disorder. Value Health 2000 3 : 40 7.
39. Nuijten M, Hadjadjeba L, Evans C et al. Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics 1998 14 : 433 45.
40. Nuijten MJ. Assessment of clinical guidelines for continuation treatment in major depression. Value Health 2001 4 : 281 94.